Claims

1. Use of a non-coding sequence of deoxyribonucleic acids for the manufacture of a medicament for treatment of a human immunodeficiency virus type 1 (HIV-1) infection, wherein the non-coding sequence of deoxyribonucleic acids comprises CCTAGGGGTT ACCACCTTCA TTGGAAAACG TTCTTCGGGG CGTTCTTAGG TGGTAACC CCTAGGGGTT ACCACCTTCA TTGGAAAACG TTCTTCGGGG CGTTCTTAGG TGGTAACC (SEQ ID NO:5).

2. The use of claim 1, wherein the non-coding sequence of deoxyribonucleic acids is combined with combination antiretroviral therapy and/or histone de-acetylase inhibitors.

3. The use of claim 1, wherein the medicament is for co-administration with combination antiretroviral therapy and/or histone de-acetylase inhibitors.

4. The use of any one of claims 1 to 3, wherein the HIV-1 infection is latent.

5. The use of any one of claims 1 to 4, wherein the non-coding sequence of deoxyribonucleic acids has a length of up to 200 nucleotides.

6. The use of any one of claims 1 to 5, wherein the non-coding sequence of deoxyribonucleic acids has a length of 116 nucleotides.

7. The use of any one of claims 1 to 6, wherein the medicament is a vaccine.

8. The use of any one of claims 1 to 7 as an adjuvant in therapeutic or prophylactic vaccination for the treatment of HIV-1.